Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest treatment of HIV Stories

2013-09-12 16:27:49

Sustained Reduction of Viral Load at or Below Limit of Detection during Treatment Interruption of Antiretroviral Therapy RICHMOND, Calif., Sept. 12, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new data from its ongoing Phase 2 clinical trial (SB-728-902 Cohort 5) to evaluate a single infusion of Sangamo's novel ZFP Therapeutic(®), SB-728-T, for the treatment of HIV/AIDS. The data demonstrate functional control of the virus at or below...

2013-08-13 00:20:51

LONDON, Aug. 12, 2013 /PRNewswire/ -- ViiV Healthcare is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved Tivicay(®) (dolutegravir) 50-mg tablets. Tivicay is an integrase inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 in adults and children aged 12 years and older weighing at least 40 kg (approx. 88 lbs). To view the multimedia assets associated with this release, please click:...

2013-08-12 20:22:08

LONDON, Aug. 12, 2013 /PRNewswire/ -- ViiV Healthcare is pleased to announce today that the U.S. Food and Drug Administration (FDA) has approved Tivicay(®) (dolutegravir) 50-mg tablets. Tivicay is an integrase inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 in adults and children aged 12 years and older weighing at least 40 kg (approx. 88 lbs). "Today is a very important milestone for patients and the scientists and teams who...

2013-03-06 12:26:23

Data Demonstrate that SB-728-T Possesses Necessary Immunologic Properties to Support a 'Functional Cure' for HIV/AIDS RICHMOND, Calif., March 6, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced new data from its program to develop a 'functional cure' for HIV/AIDS in two presentations at the 20(th) Conference on Retroviruses and Opportunistic Infections (CROI), held in Atlanta from March 3 to 6, 2013. (Logo:...

2012-05-03 06:26:49

DURHAM, N.C., May 3, 2012 /PRNewswire/ -- Argos Therapeutics Inc. today announced that study results demonstrated that analytical treatment interruption to assess the antiviral activity of Argos's Arcelis(TM) personalized immunotherapy for the treatment of HIV patients, AGS-004, is an acceptable strategy for at least 16 weeks. Study results were published in the Journal of Medical Virology (84:885-889, 2012). "Establishing the safety of analytical treatment interruptions of at least 16 weeks...

2011-05-20 10:27:00

SILVER SPRING, Md., May 20, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Edurant (rilpivirine) in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naive). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Edurant belongs to a class of HIV drugs called non-nucleoside reverse transcriptase inhibitor (NNRTI). The drug works by blocking HIV viral...

2011-03-03 06:00:00

RICHMOND, Calif., March 3, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from its programs to develop ZFN-based therapeutic approaches for the treatment of HIV/AIDS were discussed in four oral presentations at the 18th Conference on Retroviruses and Opportunistic Infections (CROI), held in Boston from February 27 to March 2, 2011. "SB-728-T is a key addition to the toolbox of technologies required to move from the bone marrow transplant setting...

2011-03-02 15:05:00

BOSTON, March 2, 2011 /PRNewswire/ -- Argos Therapeutics announced today that its Arcelis immunotherapy for the treatment of HIV, AGS-004, demonstrated positive outcomes with the primary endpoint of viral load control and a favorable safety and immunogenicity profile in a final analysis of a Phase 2a clinical trial. Data for AGS-004 were presented in a poster at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. In the study, AGS-004 was safe and well...

2011-02-28 07:30:00

RICHMOND, Calif., Feb. 28, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of positive preliminary clinical data from its Phase 1 trial (SB-728-902). The trial is being conducted in immunologic non-responders, HIV-infected subjects who are currently on highly active antiretroviral therapy (HAART) and have undetectable levels of virus but suboptimal CD4+ T-cell counts. The study is designed to evaluate safety and clinical outcomes of...

2010-05-06 07:00:00

PHILADELPHIA, May 6 /PRNewswire/ -- URL Pharma, Inc., today announced that the U.S. Food and Drug Administration (FDA) has issued new label information affecting all approved protease inhibitors for treatment of HIV when co-administered with Colcrys® (colchicine, USP). These dosing guidelines are intended to avoid potentially fatal drug-drug interactions. These new dosing recommendations were issued as a result of several clinical studies designed and conducted by URL...